BioMarin has named Cristin Hubbard as EVP and Chief Commercial Officer. Hubbard will assume responsibility for the company’s global commercial operations, effective May 20, succeeding Jeff Ajer. Hubbard served most recently as the head of Global Product Strategy for Roche Pharma, where she was responsible for lifecycle management, accelerating delivery of the company’s medicines from development to commercialization, across five therapeutic areas. Prior to that, she served as global head of Diagnostics Partnering for Roche Diagnostics. Hubbard started her career as a medicinal chemist at Theravance, before joining Roche and Genentech. Ajer will continue to lead the commercial organization until May 20. He has worked at BioMarin for more than 18 years, including 11 as chief commercial officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- New Share Price & Shareholder Rights Risk for Biomarin Pharmaceutical Inc. – What’s the Latest?
- BioMarin discloses receipt of subpoena from U.S. Department of Justice
- BioMarin price target lowered to $107 from $115 at Piper Sandler
- BioMarin price target lowered to $130 from $150 at BofA
- BioMarin sees 2024 non-GAAP EPS $2.60-$2.80, consensus $1.96
